Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04303156 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT04303156 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 12 participants.
The verdict
NCT04303156, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study will evaluate the general tolerability and pharmacokinetics (PK) of a single 60 mg dose of MK-8591 (Islatravir) in participants with severe renal insufficiency, compared to participants in good health.
Interventions
- DRUG Islatravir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-06-18 |
| Est. Completion | 2020-10-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04303156
The ClinicalTrials.gov registry entry for NCT04303156 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Islatravir is the first listed.
NCT04303156 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04303156 about?
NCT04303156 is a clinical study titled "Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)". This study will evaluate the general tolerability and pharmacokinetics (PK) of a single 60 mg dose of MK-8591 (Islatravir) in participants with severe renal insufficiency, compared to participants in good health.
What is the current status of trial NCT04303156?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2020-06-18. Estimated completion is 2020-10-19.
What interventions are being tested in trial NCT04303156?
The interventions under investigation include: Islatravir (DRUG).
Who is sponsoring clinical trial NCT04303156?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.